Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Jonna Kim’s Buy Recommendation: Hims & Hers Health’s Robust Growth Trajectory and Market Potential
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Becker's Hospital Review9h
Hims & Hers to sell generic weight loss drug in 2025
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Seeking Alpha1d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers price target raised to $32 from $28 at Seaport Research
Seaport Research raised the firm’s price target on Hims & Hers to $32 from $28 and keeps a Buy rating on the shares. The company ...
Modern Healthcare22h
Hims & Hers defends compounded GLP-1s as shortages wane
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Investor's Business Daily on MSN10h
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock rose early Tuesday after compounded weight-loss drugs helped build on a "robust" trajectory for Hims & Hers Health ...